The Reflux Company is delighted to announce a five-year exclusive distribution agreement with RD Biomed Ltd. for the Peptest (sold in the US as PepsinCheck by Peptest). PepsinCheck by Peptest is scheduled to be The Reflux Company’s second commercially available product following hot on the heels of this week’s announcement of an exclusive licensing agreement with the Medical College of Wisconsin for the Reflux Band.
The Peptest kit is a non-invasive immunological in-vitro diagnostic medical device that contains two pepsin monoclonal antibodies to identify pepsin in a clinical sample of saliva/ sputum quickly and easily. Peptest is a highly accurate diagnostic test with reported validated performance measures of up to 95% sensitivity and 89% specificity.
Thomas Ball, Founder and CEO of The Reflux Company said, “Accurate diagnostics are the cornerstone of effective patient care and disease management. Peptest’s ability to provide a reliable biomarker test for reflux makes it invaluable to a range of patients from those first exploring their symptoms to complex presentations post-surgery.”
The Reflux Company was founded in 2025 to provide patient-centered reflux solutions across the continuum of care. Further product announcements are scheduled for the coming months.
For questions or further information, please visit www.refluxcompany.com or email contact@refluxcompany.com.
